Citius Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Citius Pharmaceuticals, Inc. (CTXR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $12.76 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-12-31 was $3.47M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-12-31 was -$2.15M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-12-31 was -$6.14M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-12-31 was -$4.82M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $1.00M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$23.23M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$15.23M.
- Citius Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$28.36M, a 150.45% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.76M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $337.88K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $3.47M 10-Q · filed 2026-02-13 | |||
| 2025-09-30 | $1.00M 10-K · filed 2025-12-23 | |||
| 2025-06-30 | $2.84M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$3.23M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$2.15M 10-Q · filed 2026-02-13 | |||
| 2024-09-30 | -$23.23M 10-K · filed 2025-12-23 | |||
| 2024-06-30 | -$8.57M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$13.92M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$6.14M 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | -$15.23M 10-K · filed 2024-12-27 | |||
| 2023-06-30 | -$8.43M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$12.65M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$4.82M 10-Q · filed 2024-02-14 | |||
| 2022-09-30 | -$28.36M 10-K · filed 2023-12-29 | |||
| 2022-06-30 | -$22.03M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$14.32M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$4.65M 10-Q · filed 2023-02-10 | |||
| 2021-09-30 | $56.21M 10-K · filed 2022-12-22 | |||
| 2021-06-30 | $101.80M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $89.84M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$9.56M 10-Q · filed 2022-02-10 | |||
| 2020-09-30 | $5.97M 10-K · filed 2021-12-15 | |||
| 2020-06-30 | $623.53K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$3.55M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$5.11M 10-Q · filed 2021-02-11 | |||
| 2019-09-30 | -$1.29M 10-K · filed 2020-12-16 | |||
| 2019-06-30 | -$4.67M 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |